Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesFilamentous bacteriophage fd as an antigen delivery system in vaccinationInduction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeStructure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesBroadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingBroad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeFunctional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionHeterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesInduction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccinesCross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesStructure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5Survey of the year 2000 commercial optical biosensor literature.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloLiposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesIn vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensImmunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external regionAntigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
P2860
Q24561905-8E7CFB6B-4EB7-4B83-9824-992B5A27B555Q26864071-B514FDD5-8D27-493F-8B8B-0C9E5D082611Q27312171-B4B48823-5170-4064-9DDE-BC363EFD3A8AQ27489000-429BE3CF-E5B6-4576-B22A-ECE46741C6EEQ27657377-68A19224-50F5-488D-9DC6-9A8447C6DED9Q27675260-76599436-C017-4B2B-BEB5-1BBD2841725DQ27681352-773FF2B9-8654-47EE-8AB6-4D1606C05BFAQ28484544-67DFD842-0109-43C0-B34A-331BB3C6BDB8Q29619015-D857CA87-2078-4830-9CFE-7808BF11E86CQ31016954-8A543B30-ED7C-44B9-BABC-B22B028F9146Q31016969-336DB607-2042-4D7D-AB98-6BE4CFE00E7DQ33392865-CAA23546-884B-414B-A5A6-8CE59525E591Q33417195-C9F34775-7F99-4460-A4A7-1B4B56EEF2E0Q33508799-C136E224-64BE-42CB-8618-8BE8E9779B57Q33778466-C2D44D8F-E83E-4238-873B-EEFFC1ED2CEEQ33812812-A61EC733-2EF0-4310-BB73-A42D0B08CD63Q33826951-4683D5C0-C745-4A4D-BA64-C3EAADEA7A6BQ33842152-DAA1325B-89B1-4462-8DB7-14B4DF3D97FCQ33869882-6843FB75-5F6D-4259-8B06-40BB22D61404Q33916676-BF135B8A-55BA-4388-8FC6-736D8848AB11Q34204047-E1F0DEA3-2592-4A20-BD83-09C4907238B6Q34324992-5879A6E4-DEEE-417E-BFE4-437D2C06C3DDQ34348303-DE7015B2-DAA0-4466-A095-0DB42779CE2BQ34353296-8A6AD813-4D85-4D66-B7DC-3A6B6471D756Q34359035-E5B445DE-7AC2-4D97-96C2-F480EF38FF1CQ34396912-C1907BF2-76E2-411C-8844-5D08F289D4F2Q34434753-E94F5B07-8FB3-493D-8DA9-93194C61019CQ34464911-1D7A0DFC-C62E-4246-ACB4-64DE721AAEC9Q34543052-8A0CB797-DBE0-4134-88AB-7BB5D50280E2Q34552313-FCA10CD5-7D2D-4CC5-A4FD-625D3835359EQ34937404-1FEB8EAE-9ECE-43A5-B9C1-C80DBCB04136Q35024202-4BDB16AA-A790-4A9E-A07E-B8FDCCF88AE4Q35034311-DA1CB675-8844-4807-A626-2D6CD4A8AC8DQ35704086-DDED54A8-ADDE-4FBD-A450-8D427074DF90Q35947769-75AE65A2-ECA0-493E-95C3-F7AC0DFCB16AQ35998559-45C0630C-2A31-423F-AB41-6C0B6162F485Q36138144-B110449A-8922-45D0-8366-36038E4B36B5Q36372534-55433F68-528C-43A3-A24D-5D277F1C80C0Q36447540-CD7DF610-FCAC-400A-B6D1-1E314DD43108Q36497712-DEF5D1F1-B829-4F7D-A129-F4DBC26051F3
P2860
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@ast
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@en
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@nl
type
label
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@ast
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@en
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@nl
prefLabel
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@ast
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@en
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@nl
P2093
P3181
P1433
P1476
Antigenicity and immunogenicit ...... sive sites of the MalE protein
@en
P2093
E Coëffier
J M Clément
N Khodaei-Boorane
R El Habib
P304
P3181
P356
10.1016/S0264-410X(00)00267-X
P407
P577
2000-11-22T00:00:00Z